UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
AstraZeneca acquires vaccine partner Omniose
AstraZeneca has acquired Omniose, a vaccine startup and its development partner since a January 2024 alliance. Terms were not disclosed. The deal gives AstraZeneca Omniose's bioconjugation technology, a more efficient way to make conjugate vaccines, which it plans to use for shots against serious bacterial infections.
Why it matters: Buying the platform outright gives AstraZeneca a simpler route to making conjugate vaccines.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →